^
    Back
    Association details:
    Biomarker:FGFR2 fusion
    Cancer:Cholangiocarcinoma
    Drug:tinengotinib (TT-00420) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

    Excerpt:
    ...Documentation of FGFR2 fusion/rearrangement gene status 4....
    Trial ID:
    FIRST-308
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma

    Excerpt:
    ...- Cohort A1: FGFR2 fusions who have failed at least one previous treatment with an FGFR inhibitor...
    Trial ID:
    NCT04919642
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO-GI 2023
    Title:

    Phase II study of FGFR1-3 inhibitor tinengotinib as monotherapy in patients with advanced or metastatic cholangiocarcinoma: Interim analysis

    Published date:
    01/17/2023
    Excerpt:
    Eligible patients (pts) with advanced/metastatic CCA exhausting standard treatment options received tinengotinib 10 mg QD….Overall DCR (CR or PR+SD) was 90% (9/10) in FGFR2 fusion/rearrangement pts; 100% in FGFR primary mutation pt (1/1)....The preliminary biomarker analysis suggests loss of resistant FGFR mutation on liquid biopsy post tinengotinib therapy....Tinengotinib may result in promising clinical benefit for CCA pts in the setting of FGFRi-resistance.
    DOI:
    10.1200/JCO.2023.41.3_suppl.539
    Trial ID:
    NCT04919642